DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting
Châtillon, France, June 11, 2025
DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting
Shareholders approved all proposed resolutions
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the 'Company'), held its Combined General Meeting (the 'General Meeting'). The General Meeting was chaired by Michel de Rosen, Chairman of the Company.
The Company's shareholders approved all resolutions submitted by the Board of Directors. The resolutions and the voting results are posted on the Investors/Annual General Meetings section of the Company's website: https://dbv-technologies.com/events/2025-annual-general-meeting/.
About DBV TechnologiesDBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary technology platform, Viaskin™, to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the Viaskin platform is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual's underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin's immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company's food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company's ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).
For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.
Viaskin and EPIT are trademarks of DBV Technologies.
Investor Contact Katie MatthewsDBV Technologieskatie.matthews@dbv-technologies.com
Media ContactAngela Marcucci DBV Technologiesangela.marcucci@dbv-technologies.com
Attachment
PDF VersionFehler beim Abrufen der Daten
Melden Sie sich an, um Ihr Portfolio aufzurufen.
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Radisson Announces Results of its Annual and Special Meeting of Shareholders
Rouyn-Noranda, Quebec--(Newsfile Corp. - June 12, 2025) - Radisson Mining Resources Inc. (TSXV: RDS) (OTCQB: RMRDF) ("Radisson" or the "Company) is pleased to announce the results of its Annual and Special Meeting of Shareholders ("AGM") held on June 12, 2025. Shareholders voted in favour of all items of business, including the election of each director nominee, the appointment of auditors, and the adoption of a new Omnibus Equity Incentive Plan. A total of 156,469,851 votes were represented in the meeting amounting to 45.22% of the Company's class A shares issued as of the record date. Directors re-elected to the board were Pierre Beaudoin, Lise Chénard, Michael Gentile, Peter MacPhail, Matt Manson, Jeff Swinoga and Cindy Valence. Subsequent to the AGM, Pierre Beaudoin was re-appointed as Chairperson of the Board of Directors. New Omnibus Equity Incentive Plan The new Omnibus Equity Incentive Plan (the "Omnibus Plan") replaces the Company's previous stock option plan and introduces a best-practice framework to attract and retain personnel through a broader range of equity-based awards. Under the Omnibus Plan, a rolling 10% share reserve will apply to all awards, including stock-options ("Options"), restricted share units ("RSUs"), performance share units ("PSUs"), and deferred share units ("DSUs"). The total number of common shares reserved for issuance under the Omnibus Plan, at any time, will not exceed 10% of the Company's issued and outstanding common shares. All outstanding stock-options granted under the previous plan will continue under the Omnibus Plan, unless the new plan materially impairs the rights of existing holders, in which case the terms of the original plan will remain in effect. A full copy and summary of the Omnibus Plan is available in the Company's management information circular dated May 7, 2025, which can be accessed under Radisson's profile at and on the Company's website at Grant of Equity Incentives Subsequent to the AGM, the Board of Directors authorized the grant of an aggregate of 2,739,014 stock-options, to directors, officers, employees and consultants of the Company. The Options have an exercise price of $0.425 per share, are exercisable for a period of five-years from the date of grant and will vest as follows: one-third on the date of grant, one-third on the first anniversary of the date of grant and one-third on the second anniversary. In addition, the Board of Directors authorized the grant of an aggregate 966,416 RSUs to officers of the Company and 541,176 DSUs to independent directors of the Company. A total of 262,004 RSUs vest on the first anniversary of the date of grant. The balance of the RSUs vest as follows: one-third on the first anniversary of the date of grant, one-third on the second anniversary and one-third on the third anniversary. The Options, RSUs and DSUs were granted in accordance with the Omnibus Plan. Radisson Mining Resources Inc. Radisson is a gold exploration company focused on its 100% owned O'Brien Gold Project, located in the Bousquet-Cadillac mining camp along the world-renowned Larder-Lake-Cadillac Break in Abitibi, Québec. The Bousquet-Cadillac mining camp has produced over 25 million ounces of gold over the last 100 years. The Project hosts the former O'Brien Mine, considered to have been Québec's highest-grade gold producer during its production. Indicated Mineral Resources are estimated at 0.50 million ounces (1.52 million tonnes at 10.26 g/t Au), with additional Inferred Mineral Resources estimated at 0.45 million ounces (1.60 million tonnes at 8.66 g/t Au). Please see the NI 43-101 "Technical Report on the O'Brien Project, Northwestern Québec, Canada" effective March 2, 2023 and other filings made with Canadian securities regulatory authorities available at for further details and assumptions relating to the O'Brien Gold Project. For more information on Radisson, visit our website at or contact: Matt MansonPresident and CEO416.618.5885mmanson@ Kristina PillonManager, Investor Relations604.908.1695kpillon@ Forward-Looking Statements This news release contains "forward-looking information" within the meaning of the applicable Canadian securities legislation that is based on expectations, estimates, projections, and interpretations as at the date of this news release. Forward-looking statements including, but are not limited to, statements with respect to the closing of the Offering, the planned and ongoing drilling, the significance of drill results, the ability to continue drilling, the impact of drilling on the definition of any resource, the ability to incorporate new drilling in an updated technical report and resource modelling, the Company's ability to grow the O'Brien project and the ability to convert inferred mineral resources to indicated mineral resources. Any statement that involves discussions with respect to predictions, expectations, interpretations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "interpreted", "management's view", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information and are intended to identify forward-looking information. Except for statements of historical fact relating to the Company, certain information contained herein constitutes forward-looking statements Forward-looking information is based on estimates of management of the Company, at the time it was made, involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the companies to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Such factors include, among others, risks relating to the drill results at O'Brien; the significance of drill results; the ability of drill results to accurately predict mineralization; the ability of any material to be mined in a matter that is economic. Although the forward-looking information contained in this news release is based upon what management believes, or believed at the time, to be reasonable assumptions, the parties cannot assure shareholders and prospective purchasers of securities that actual results will be consistent with such forward-looking information, as there may be other factors that cause results not to be as anticipated, estimated or intended, and neither the Company nor any other person assumes responsibility for the accuracy and completeness of any such forward-looking information. The Company believes that this forward-looking information is based on reasonable assumptions, but no assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this press release should not be unduly relied upon. The Company does not undertake, and assumes no obligation, to update or revise any such forward-looking statements or forward-looking information contained herein to reflect new events or circumstances, except as may be required by law. These statements speak only as of the date of this news release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30 minutes ago
- Yahoo
New to The Street Launches Arrive AI TV Commercials Across its Full Media Ecosystem
The campaign will air nationally on CNBC, FOX Business, Bloomberg, and inside NTTS's weekly investor-focused television broadcasts-along with distribution across New to The Street's 2.6M YouTube subscriber channel. NEW YORK CITY, NY / / June 12, 2025 / New to The Street, a leading multi-platform financial media brand, proudly announces the launch of a new national commercial campaign for its featured client, Arrive AI (NASDAQ:ARAI). The high-impact TV commercial will be distributed across major financial news networks including CNBC, FOX Business, and Bloomberg, and will be fully integrated into New to The Street's weekly syndicated TV series reaching more than 220 million U.S. homes. View commercial now: The spot will also air across New to The Street's powerful digital network-including its YouTube channel with over 2.6 million subscribers, one of the largest financial video audiences in the world. The campaign shines a spotlight on Arrive AI's patented autonomous delivery platform, emphasizing its smart mailbox technology, U.S. patent portfolio, and its game-changing use cases in healthcare, e-commerce, and temperature-sensitive logistics. It's a critical moment of visibility for the company as it accelerates commercialization and expands across new sectors. "Arrive AI is one of the most compelling companies we've ever featured," said Vince Caruso, Creator and Host of New to The Street. "This TV campaign will bring their message to millions of investors, partners, and consumers across all our channels-network TV, outdoor, digital, and our 2.6M-strong YouTube community. We're proud to help tell their story at scale." The commercial will be seen: Inside New to The Street's nationally broadcast segments on FOX Business and Bloomberg On CNBC through targeted prime-time media placements Digitally across New to The Street's YouTube Channel (2.6M+ subscribers) Programmatically distributed across OTT platforms and digital pre-roll Through Accel Media's iconic outdoor billboard network including Times Square and NYC Financial District The full-scale media rollout is expected to support upcoming milestones for Arrive AI, including new strategic partnerships, vertical expansion, and additional product announcements. About Arrive AI (NASDAQ:ARAI):Arrive AI is building the future of smart logistics with its patented Arrive Points™-AI-powered mailboxes designed to securely manage both autonomous and traditional package deliveries. With eight issued patents and a growing presence in healthcare, e-commerce, and industrial delivery, Arrive AI is revolutionizing last-mile fulfillment infrastructure. About New to The Street:New to The Street is a nationally televised business show that features public and private companies, airing as sponsored programming on FOX Business, Bloomberg, and CNBC. It also operates one of the largest financial YouTube channels in the U.S. with over 2.6 million subscribers, supported by robust earned media, digital distribution, and outdoor advertising in Times Square and the NYC Financial District. Media Contact:Monica BrennanPR, New to The StreetMonica@ Investor Contact:Dan O'Toole, CEO, Arrive AIir@ SOURCE: New To The Street View the original press release on ACCESS Newswire Connectez-vous pour accéder à votre portefeuille
Yahoo
2 hours ago
- Yahoo
Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs
If Approved, NUMELVI Will Be the First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Treatment of Pruritus Associated with Allergic Dermatitis Including Atopic Dermatitis and Treatment of Clinical Manifestations of Atopic Dermatitis in Dogs RAHWAY, N.J., June 12, 2025--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Medicines Agency's Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs. NUMELVI, a once-daily, first-line treatment, will be the only second-generation Janus kinase (JAK) inhibitor indicated for the treatment of pruritus associated with allergic dermatitis including atopic dermatitis and treatment of clinical manifestations of atopic dermatitis in dogs, upon full approval by the European Commission. NUMELVI inhibits the function of JAK1-dependent cytokines involved in itch and inflammation in allergic and atopic dermatitis and is at least 10-fold more selective for JAK1 compared to the other JAK family members (JAK2, JAK3 and TYK2). JAK1 selectivity minimizes interference with cytokines involved in hematopoiesis and immune functions dependent on the other JAKs, resulting in a compelling safety profile with proven efficacy in dogs and puppies. Once approved, it will be the only JAK inhibitor that can be used in dogs as young as six months of age. With a once-daily treatment regimen, NUMELVI is clinically effective after the first dose. Treatment with NUMELVI had no impact on immune response to vaccination. "Merck Animal Health has been committed to bringing innovation to our customers aimed at rapidly controlling and treating a common condition that causes distress for so many pets and pet owners," said Rick DeLuca, executive vice president and president, Merck Animal Health. "With today's positive opinion for NUMELVI, we are one step closer to making this novel, highly selective JAK inhibitor available." Itch is seen in more than 20 percent of dogs in general veterinary practice and is one of the most frequent reasons for veterinary visits. As allergic dermatitis progresses, quality of life in dogs declines and the relationship between a pet and its owner can be weakened due to emotional distress, interruptions in sleep and routines, increased expenses, and time lost to provide treatment and veterinary follow-up to manage an itchy dog. Veterinarians also face challenges in managing dogs with allergic dermatitis, as diagnosis and treatment takes time and requires regular progress checks. "Merck Animal Health continues to deliver cutting-edge innovation and science with first- and best-in-class veterinary medicinal products that address important unmet needs," said Holger Lehmann, DVM, PhD, vice present and global head, research and development for pharmaceuticals, Merck Animal Health. "NUMELVI not only offers a once-daily dosing regimen but also features a distinctive safety profile that permits its use in dogs as young as six months. Additionally, a vaccine response study has shown that NUMELVI does not affect the immune response to core vaccinations." Based on the CVMP's recommendation, the European Commission is expected to issue a decision for marketing authorization in the European Union (EU) during the third quarter of 2025. About Merck Animal Health At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we've been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world's most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global animal health business of Merck. Through its commitment to The Science of Healthier Animals®, Merck Animal Health offers veterinarians, farmers, producers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability and monitoring products. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit and connect with us on LinkedIn, Facebook, X (formerly Twitter) and Instagram. Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2024 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site ( View source version on Contacts Media:Kim Gorode973-255-8094ahglobalmedia@ Investor:Peter
